What analysts say:
- Buy, sell, or hold?: Analysts strongly back Medifast, with four of seven rating it a buy and the remainder rating it a hold. Analysts haven't adjusted their rating of Medifast for the past three months.
- Revenue Forecasts: On average, analysts predict $71 million in revenue this quarter. That would represent a rise of 12.6% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of 21 cents per share. Estimates range from 16 cents to 27 cents.
What our community says:
CAPS All Stars are in strong support of the stock, with 78.3% giving it an "outperform" rating. The community at large agrees with the All Stars, with 84.1% awarding it a rating of "outperform." Medifast's bearish CAPS rating of two out of five stars falls short of the Fool community sentiment.
Medifast's profit has risen year-over-year by an average of 9.4% over the past five quarters.
One final thing: If you want to keep tabs on Medifast movements, and for more analysis on the company, make sure you add it to your Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.